**Table S2** Peripheral vascularization at the end of the core study and at 1 year.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **complete vascularization of the peripheral retina to**  **within one disc diameter of the ora serrata** | |  |  |  |
| **ranibizumab**  **0.12 mg** | **ranibizumab**  **0.20 mg** | **total** |
| **(N=18 eyes)** | **(N=14 eyes)** | **(N=32 eyes)** |
| **n (%)** | **n (%)** | **n (%)** |
|  |  |  |
| **at the end of the core study** | yes [N, eyes (%)] | 9 (50.0) | 3 (21.4) | 12 (37.5) |
| no [N, eyes (%)] | 6 (33.3) | 10 (71.4) | 16 (50.0) |
| missing values [N, eyes] | 3 (16.7) | 1 (7.1) | 4 (12.5) |
|  |  |  |  |
|  |  |  |  |  |
| **at 1 year post baseline** | yes [N, eyes (%)] | 8 (44.4) | 9 (64.3) | 17 (53.1) |
| no [N, eyes (%)] | - | - | - |
| missing values [N, eyes] | 10 (55.6) | 5 (35.7) | 15 (46.9) |
|  |  |  |  |  |